Medicines Co.

Medicines is a biopharmaceutical company. The company is focused on inclisiran, an investigational agent which is a lipid-lowering drug, to reduce low-density lipoprotein-cholesterol, which is referred to as bad cholesterol, in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company's products include: Angiomax, which - Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound; and Ionsys (fentanyl iontophoretic transdermal system), which is a compact, needle-free patient-controlled system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.
  • TickerMDCO
  • ISINUS5846881051
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

Increased risk weighs on THE MEDICINES CO., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of THE MEDICINES CO. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 18, 2019, the closing price was USD 35.83 and its target price was estimated at USD 26.36.

ValuEngine Rating and Forecast Report for MDCO

ValuEngine Rating and Forecast Report for MDCO

MarketLine Department

The Medicines Company – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Gold appears to be developing a potential head-and-shoulders bottom. A break above the $128 level would be very bullish. (ex. GLD and GDX) • A number of restaurants are bullishly inflecting, trending up and to the right. (ex. JACK, DIN, SHAK, and YUM) • REIT's continue to be leadership (ex. PSB, HCP, HR, WELL, ARE, ESS, MAA, AMT, CCI, and SBAC)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: Home builders and suppliers continue to outperform and one supplier, MHK, appears to be bottoming. A number of Financial names continue to plod up and to the right (e.g. AMP, AXP, MSCI, RNR) The Technology Sector remains leadership and many names continue to outperform (e.g. SEDG, SNPS, ADBE, TTEC, GPN, PYPL)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch